Heart failure & cardiomyopathies
Impact of early in-hospital initiation of sacubitril/valsartan on left ventricular reverse remodelling in acute heart failure
Authors' conclusion
Early Sac/Val initiation after hospitalization for AHF may significantly improve LV function and morphology at 8 weeks, particularly in patients with an LVEF < 40%, supporting its role in LV reverse remodelling.
Study context
- Population
- Patients hospitalized for acute HF with available echocardiographic datawith echocardiographic data
- Participants
- 206 patients
- Comparison
- Sac/Val vs standard RAS inhibitor therapy
- Sac/Valn = 94
- Controln = 112reference
- Primary endpoint
- Echocardiographic LV remodelling parameters
- Follow-up
- 8 weeks
Methodological detailssub-analysis
- Sub-analysis
Primary result
As reported in the abstract
Echocardiographic parameters
Mean
−5.1 mL/m²
95% CI −10.2 to −0.04P = 0.048
Left ventricular (LV) end-diastolic volume index
Mean
−0.17 m/s
95% CI −0.31 to −0.03P = 0.016
tricuspid regurgitation peak velocity
Further findings
Reverse remodelling by LV ejection fraction (LVEF) (subgroup)
- Reverse remodelling effect primarily in patients with LVEF < 40%
Original publication
Impact of early in-hospital initiation of sacubitril/valsartan on left ventricular reverse remodelling in acute heart failure. Eur Heart J Cardiovasc Pharmacother. Published 30 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →